Background Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not
have a sustained virologic response to therapy with peginterferon alfa plus ribavirin. Methods …

Background In phase 2 studies, treatment with the all-oral combination of the nucleotide
polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of …

The family of interferon (IFN) proteins has now more than reached the potential envisioned
by early discovering virologists: IFNs are not only antivirals with a spectrum of clinical …

Background In phase 2 trials, treatment with the combination of the nucleotide polymerase
inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained …

Background Although the addition of the HCV NS3/4A protease inhibitors boceprevir and
telaprevir to pegylated interferon (peginterferon) alfa plus ribavirin has improved sustained …

Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs
(PWID) cannot be achieved by harm reduction interventions such as needle exchange and …

Advances in tissue bioengineering, such as the development of biologically useful cells,
tissue, and organs, are expected to revolutionise the practice of medicine. 1 Living skin …

Background & Aims All oral direct acting antivirals (DAAs) effectively treat chronic hepatitis C
virus (HCV) infection, but the benefits in advanced liver disease are unclear. We compared …

Patients with chronic hepatitis C virus (HCV) infection frequently report fatigue, lassitude,
depression, and a perceived inability to function effectively. Several studies have shown that …

Background Glecaprevir and pibrentasvir are direct-acting antiviral agents with pangenotypic
activity and a high barrier to resistance. We evaluated the efficacy and safety of 8-week …